PT  - JOURNAL ARTICLE
AU  - Cheng Zhang
AU  - Li-Xian Qian
AU  - Jian-Qiang Hu
TI  - Pathways of the COVID-19 Pandemic with Human Mobility across Countries
AID  - 10.1101/2020.05.21.20108589
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.21.20108589
4099  - http://medrxiv.org/content/early/2020/05/23/2020.05.21.20108589.short
4100  - http://medrxiv.org/content/early/2020/05/23/2020.05.21.20108589.full
AB  - This study develops a holistic view of the novel coronavirus (COVID-19) transmission worldwide through a spatial-temporal model with network dynamics. By using a unique human mobility dataset containing 547,166 flights with a total capacity of 101,455,913 passengers among 22 countries during the past three months, we analyze the associations between international travel movement in six continents and the new infections in these countries. Results show that policymakers should move away from the previous practices that focus only on restricting hotspot areas with high transmission rates. Instead, they should develop a new holistic view of global human mobility to adjust the international movement restriction. The study highlights that international human mobility is the key to understand the transmission pathways and the small world phenomenon in the global network of COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was partially supported by the National Natural Science Foundation of China (No. 91846302, 71720107003, 71973107).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N.A.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request.